Slide background

C4X Discovery

Building the world's most productive drug discovery engine

Slide background

Proprietary Technologies

Designing and creating best-in-class drug candidates

Slide background

Small Molecule Drugs

Novel medicines across broad therapeutic areas

Slide background

Target Discovery

Proprietary genetic analysis to reveal unique targets

Slide background

C4X Discovery

Building the world's most productive drug discovery engine

Slide background

Proprietary Technologies

Designing and creating best-in-class drug candidates

Slide background

Small Molecule Drugs

Novel medicines across broad therapeutic areas

Slide background

Target Discovery

Proprietary genetic analysis to reveal unique targets

Slide background

C4X DISCOVERY

Building the world's most productive drug discovery engine

Slide background

Proprietary Technologies

Designing and creating best-in-class drug candidates

Slide background

Small Molecule Drugs

Novel medicines across broad therapeutic areas

Slide background

Target Discovery

Proprietary genetic analysis to reveal unique targets

Our Progress

Discovery Programmes
Novel genes discovered by Taxonomy3®
4D-Structures Solved

Taking Pharmaceutical Discovery to the Next Level in Unreal Engine

Read More...

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurology and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.

You must have the Adobe Flash Player installed to view this player.

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurology and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.

UNIQUE

UNIQUE DRUG DISCOVERY ENGINE

utilising in vitro 3D shapes of drug molecules with unique software "Conformetrix" discovering more potent drugs faster

Read More

Hybrid

HYBRID BUSINESS MODEL

of wholly-owned pipeline of programmes plus partnerships with Pharma and Biotech

Read More

Management

STRENGTH OF MANAGEMENT

team with track record of value creation


Read More

Genetics

HUMAN GENETICS PLATFORM

"Taxonomy3" that provides proprietary target discovery & validation to ‘fuel’ the discovery engine

Read More

Molecules

SMALL MOLECULE DRUG

design and creation of best-in-class molecules including switch of clinically validated biologic based therapies (mAbs, peptides)

Read More

UNMET NEED

HIGH UNMET MEDICAL NEED

across multiple broad therapeutics areas to be targeted and exploited by C4XD’s cutting-edge technologies

Read More

Chief Financial Officer Brad Hoy
Brad has more than 20 years’ experience in the pharmaceutical and biotechnology industries.
Chief Executive Officer Dr Clive Dix
Clive has over 30 years' experience in the pharmaceutical and biotechnology industries.
Head of Corporate Strategy and Development Bhavna Hunjan
Bhavna has 10 years’ experience across investment banking and strategic consultancy, providing commercial advice.
Chief Scientific Officer Dr Craig Fox
Craig has more than 20 years’ drug discovery experience from target selection to Phase 2 clinical studies.
Chief Executive Officer Dr Clive Dix
Clive has over 30 years' experience in the pharmaceutical and biotechnology industries.
Chief Scientific Officer Dr Craig Fox
Craig has more than 20 years’ drug discovery experience from target selection to Phase 2 clinical studies.
Head of Corporate Strategy and Development Bhavna Hunjan
Bhavna has 10 years’ experience across investment banking and strategic consultancy, providing commercial advice.
Chief Financial Officer Brad Hoy
Brad has more than 20 years’ experience in the pharmaceutical and biotechnology industries.
We believe C4X’s Orexin-1 program is one of the most promising early stage programs to potentially treat addiction and look forward to rapidly advancing lead compound C4X3256 into the clinic
- Christian Heidbreder, Chief Scientific Officer of Indivior
Our licensing agreement with Indivior, a world-leader in developing and commercialising treatments for addiction, highlights the ability of our drug discovery engine to generate best-in-class small-molecule candidates in high value therapeutic areas.
- Dr Clive Dix, Chief Executive Officer of C4XD
We are delighted to have secured this collaboration with C4X Discovery, which applies a powerful drug discovery engine to the first-in-class opportunities for transformational medicines.
- Dr Jon Moore, Horizon’s Chief Scientific Officer at Horizon Discovery
LifeArc is delighted to partner with C4XD. Our new partner’s expertise in the rapid design and analysis of novel small molecule therapeutics complements LifeArc’s drug discovery expertise.
- Dr Justin Bryans, Executive Director, Drug Discovery at LifeArc